Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. (noting a discrepancy with the metadata name "Cypherpunk Technologies Inc.") on September 9, 2020. The report details corporate governance actions taken on September 9 and September 10, 2020, regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and structural amendments rather than financial performance.
Material Changes
- Elimination of Preferred Stock: The Company filed Certificates of Elimination for its Series A and Series B Mandatorily Convertible Cumulative Non-Voting Perpetual Preferred Stock.
- Outstanding Shares: No shares of Series A or Series B Preferred Stock were outstanding at the time of filing.
- Charter Amendment: On September 10, 2020, the Company filed a Fourth Amended and Restated Certificate of Incorporation to reflect these eliminations.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural report of corporate filings with the Delaware Secretary of State.
Investor Verification Checklist
- Verify the correct registrant name is Leap Therapeutics, Inc. (Ticker: LPTX), as the metadata provided an incorrect name.
- Confirm that the elimination of Series A and Series B Preferred Stock aligns with the company's current capitalization table.
- Review the attached Fourth Amended and Restated Certificate of Incorporation (Exhibit 3.3) for any other structural changes.